MARKET

IMMP

IMMP

Immutep
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.520
+0.320
+10.00%
After Hours: 3.520 0 0.00% 17:07 05/07 EDT
OPEN
3.310
PREV CLOSE
3.200
HIGH
3.520
LOW
3.240
VOLUME
542.77K
TURNOVER
--
52 WEEK HIGH
7.95
52 WEEK LOW
0.9300
MARKET CAP
228.35M
P/E (TTM)
-0.8128
1D
5D
1M
3M
1Y
5Y
Immutep Says Have Sufficient Cash to Fund Operations into 2023
MT Newswires · 7h ago
BRIEF-Immutep Operational Update
reuters.com · 10h ago
Immutep Reported AIPAC Phase IIb Clinical Trial Reached ~72% of Events; TACTI-002 Study Recruited 54 of Up to 110 Patients Enrolled; Said has Cash Runway into CY 2023
Immutep Limited (NASDAQ: IMMP) provides an update on its clinical and preclinical programs. Eftilagimod alpha ("efti") Update AIPAC - Phase IIb clinical trial The Company is on track to report final overall survival (OS) data from this metastatic breast ca...
Benzinga · 12h ago
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new ...
GlobeNewswire · 04/28 15:21
What Type Of Shareholders Own The Most Number of Immutep Limited (ASX:IMM) Shares?
A look at the shareholders of Immutep Limited ( ASX:IMM ) can tell us which group is most powerful. Insiders often own...
Simply Wall St. · 04/25 20:37
FOCUS-Pandemic prompts European life sciences real estate rush
reuters.com · 04/20 06:00
Immutep Quarterly Activities Report
Highlights Safely dosed the last HNSCC patient for Stage 2 of Part C of the TACTI-002 Phase II study (also designated KEYNOTE-798)Initiated enrolment of first line NSCLC patients for the expansion arm of Part A of TACTI-002Commenced recruitment of second l...
GlobeNewswire · 04/19 12:00
Immutep Receives A$1,155,055 R&D Tax Incentive
SYDNEY, AUSTRALIA, April 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate from the Australian Federal Government’s R&D tax incentive pr...
GlobeNewswire · 04/16 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMMP. Analyze the recent business situations of Immutep through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMMP stock price target is 7.05 with a high estimate of 8.06 and a low estimate of 6.04.
EPS
Institutional Holdings
Institutions: 17
Institutional Holdings: 680.10K
% Owned: 1.05%
Shares Outstanding: 64.87M
TypeInstitutionsShares
Increased
2
96.02K
New
6
100.06K
Decreased
0
0
Sold Out
1
38.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Non-Executive Chairman
Russell Howard
Chief Executive Officer/Executive Director
Marc Voigt
Non-Executive Vice Chairman
Pete Meyers
Chief Operating Officer/General Counsel/Secretary
Deanne Miller
Chief Scientific Officer
Frederic Triebel
Non-Executive Director
Grant Chamberlain
No Data
About IMMP
Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

Webull offers kinds of Immutep Ltd stock information, including NASDAQ:IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.